Results 101 to 110 of about 19,808 (220)

Radiolabelled peptides for oncological diagnosis [PDF]

, 2012
Radiolabelled receptor-binding peptides targeting receptors (over)expressed on tumour cells are widely under investigation for tumour diagnosis and therapy.
Peter Laverman, Jane K. Sosabowski, Otto C. Boerman, Wim J. G. Oyen   +3 more
core   +1 more source

Seasonal changes in brain serotonin transporter binding in short 5-HTTLPR-allele carriers but not in long-allele homozygotes [PDF]

, 2008
Several findings suggest seasonal variations in the serotonin (5-HT) system. We sought evidence for seasonal variation in the serotonin transporter (5-HTT).
David Erritzoe, Finn A. Nielsen, Gitte M. Knudsen, Jan Kalbitzer, Klaus K. Holst, Lisbeth Marner, Szabolcs Lehel, Terry L. Jernigan, Tine Arentzen   +8 more
core   +1 more source

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy

Indian Journal of Radiology and Imaging
Objective [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging ...
Dheeratama Siripongsatian, Attapon Jantarato, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Peerapon Kiatkittikul, Natphimol Boonkawin, Sukanya Yaset, Sirinsuda Somboon, Chanisa Chotipanich   +8 more
doaj   +1 more source

Unlocking New Therapeutic Strategies in Oligometastatic Prostate Cancer with Radioligand and Metastasis-directed Radiation Therapy

European Urology Open Science
By delivering targeted radiation to tumor cells with a minimal impact on healthy tissues, radioligand therapy (RLT) has become an established treatment for metastatic castration-resistant prostate cancer.
Salvatore Cozzi, Camille Roukoz, Thomas Zilli   +2 more
doaj   +1 more source

Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology

Cancer Treatment Reviews
Radioligand therapy (RLT) represents a promising advancement in precision oncology and enables the targeted delivery of radiation to cancer cells. This approach has shown success in other tumor types, such as prostate cancer and neuroendocrine tumors. Its potential in metastatic breast cancer (mBC) is currently under investigation.
Giugliano, Federica, Giordano, Elisa, Gilardi, Laura, Salimbeni, Beatrice Taurelli, Zagami, Paola, Esposito, Angela, Marra, Antonio, Trapani, Dario, Berton Giachetti, Pier Paolo Maria, Malagutti, Bianca, Henry, Théophraste, Deandreis, Desiree, Curigliano, Giuseppe, Ceci, Francesco, Criscitiello, Carmen   +14 more
openaire   +3 more sources

Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome. [PDF]

, 2019
Dravet syndrome is a life-threatening early-onset epilepsy not well controlled by antiepileptic drugs. Drugs that modulate serotonin (5-HT) signalling, including clemizole, locaserin, trazodone and fenfluramine, have recently emerged as potential ...
Baraban, Scott C, Grandjean, Jean-Marc, Griffin, Aliesha L, Jaishankar, Priyadarshini, Olson, Steven H, Renslo, Adam R   +5 more
core   +1 more source

La radioligand therapy (RLT) nei tumori neuroendocrini

L'Endocrinologo
SommarioI tumori neuroendocrini (NET) sono un gruppo di neoplasie rare e spiccatamente eterogenee, spesso diagnosticate già in fase avanzata. Sulla scorta dei risultati dello studio NETTER-1, la terapia con radioligandi (RLT) è stata approvata da EMA, FDA e, nel 2019, da AIFA, diventando un pilastro nel trattamento dei NET gastro-entero-pancreatici ...
Ilham Badrane, Luca Urso, Alberto Nieri, Maria Luisa De Rimini, Mirco Bartolomei   +4 more
openaire   +1 more source

Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology

Current Oncology
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents,
Anupam Batra, Daniel Glick, Mario Valdes
doaj   +1 more source

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

EJNMMI Radiopharmacy and Chemistry
Background Radiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of rhPSMA-ligands developed for radioligand therapy, two stereoisomers [177Lu]Lu-rhPSMA-10.1 and -10.2 have been ...
Alexander Wurzer, Francesco De Rose, Sebastian Fischer, Markus Schwaiger, Wolfgang Weber, Stephan Nekolla, Hans-Jürgen Wester, Matthias Eiber, Calogero D’Alessandria   +8 more
doaj   +1 more source

PSMA-Directed Theranostics in Prostate Cancer

Biomedicines
Following lung cancer, prostate cancer is the leading cause of cancer death in men. High-risk localized tumor burden or metastatic disease often progresses, refractory to initial treatment regimens.
Salman Ayub Jajja, Nandini Sodhi, Ephraim E. Parent, Parminder Singh   +3 more
doaj   +1 more source